Latest BioAge Labs News & Updates

See the latest news and media coverage for BioAge Labs. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
BioAge Labs

Biotech developing therapies targeting metabolic aging

bioagelabs.com
Headquarters
Emeryville, United States
Founded year
2015
Company type
Public company
Number of employees
90–200

Latest news about BioAge Labs

Company announcements

  • BioAge Labs

    BioAge reports positive Phase 1 data for BGE-102

    BGE-102 achieves ≥85% median hsCRP reductions at 60 mg and 120 mg doses in obese participants. Well tolerated. Phase 2 trials in cardiovascular risk and DME planned for mid-2026.

  • BioAge Labs

    BioAge Labs reports 2025 financial results

    Announces positive Phase 1 data for BGE-102, plans Phase 2 trials, completes $132.3M offering. Cash funds operations through 2029.

  • BioAge Labs

    BioAge announces pricing of upsized $115 million public offering

    Offers 5,897,435 shares at $19.50 each. Proceeds fund research, clinical development of BGE-102, NLRP3, and APJ programs. Closing expected January 23, 2026.

  • BioAge Labs

    BioAge announces BGE-102 expansion to diabetic macular edema

    Plans Phase 1b/2a trial in mid-2026 to show ocular target engagement. Runs parallel to CV risk trial with results in 2H26. Preclinical data supports retinal protection.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about BioAge Labs

Track BioAge Labs and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BioAge Labs competitors & trending companies

Browse news for competitors to BioAge Labs and other trending companies.